Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Interstitial pneumopathy caused by melphalan].

F Lustman, A Salhadin, J P Dufrane

    Revue Des Maladies Respiratoires
    |January 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Mesocolon liposarcoma: a case report].

    Revue medicale de Bruxelles·2006
    Same author

    [Buccal ulcerations in an Ecuadorian patient].

    Revue medicale de Bruxelles·2005
    Same author

    Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001
    Same author

    [Bilateral breast masses].

    Revue medicale de Bruxelles·2000
    Same author

    Natural killer-like T-cell lymphoma of the stomach.

    Scandinavian journal of gastroenterology·1999
    Same author

    Progressive mediastinal widening after therapy for Hodgkin's disease. Association of Hodgkins disease with sarcoidosis.

    Acta clinica Belgica·1996
    Same journal

    [French version of the guidelines for connective tissue disease-associated ILD].

    Revue des maladies respiratoires·2026
    Same journal

    [Pulmonary expression of an asymptomatic lysosomal storage disorder].

    Revue des maladies respiratoires·2026
    Same journal

    [Factors associated with FEV1 evolution in cystic fibrosis patients treated by CFTR modulator tritherapy].

    Revue des maladies respiratoires·2026
    Same journal

    [Subacute pulmonary coccidioidomycosis: A differential diagnosis of lung cancer].

    Revue des maladies respiratoires·2026
    Same journal

    [Relevance of the ACT score in severe asthma with obesity: A pilot study].

    Revue des maladies respiratoires·2026
    Same journal

    [Automated analysis of mandibular movements for the screening of obstructive sleep apnea].

    Revue des maladies respiratoires·2026
    See all related articles

    This case report details interstitial pneumonia caused by Melphalan, a chemotherapy drug. Researchers suggest hypersensitivity may contribute to this rare pulmonary toxicity, even with low doses.

    Area of Science:

    • Pulmonology
    • Oncology
    • Toxicology

    Background:

    • Cytotoxic chemotherapy agents, including Melphalan, are known for potential systemic toxicities.
    • Pulmonary complications are a recognized, albeit less common, side effect of certain chemotherapeutic agents.
    • Understanding drug-induced lung injury is crucial for patient safety in cancer treatment.

    Observation:

    • A case of interstitial pneumonia is presented in a patient exposed to Melphalan (1-phenyl alanine).
    • The patient received low doses of the cytotoxic agent with a short latency period before pneumonopathy onset.
    • A diagnosis of lung myeloma was ruled out, focusing the etiology on the chemotherapeutic agent.

    Findings:

    • The presented case aligns with documented instances of Melphalan-induced interstitial pneumonia.

    Related Experiment Videos

  • Comparison with five similar cases suggests a potential role for hypersensitivity in the development of the pulmonary lesions.
  • The study reviews various cytotoxic drugs capable of inducing pulmonary damage and their underlying mechanisms.

    • Implications:

    • This report highlights the importance of considering Melphalan as a potential cause of interstitial pneumonia.
    • Early recognition and diagnosis of drug-induced lung disease are vital for appropriate patient management.
    • Further investigation into hypersensitivity mechanisms could refine prevention and treatment strategies for chemotherapy-related pulmonary toxicity.